• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Current status, challenges and strategy of combination treatment of local interventional therapy and immunotherapy for primary hepatocellular carcinoma].

作者信息

Hu H T, Guo C Y, Zhao X H, Li H L

机构信息

Department of Minimally Interventional Radiology, the Affiliated Cancer Hospital of zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.

出版信息

Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):455-459. doi: 10.3760/cma.j.cn112138-20220317-00187.

DOI:10.3760/cma.j.cn112138-20220317-00187
PMID:35488591
Abstract
摘要

相似文献

1
[Current status, challenges and strategy of combination treatment of local interventional therapy and immunotherapy for primary hepatocellular carcinoma].
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):455-459. doi: 10.3760/cma.j.cn112138-20220317-00187.
2
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.可切除肝细胞癌的新辅助免疫治疗
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):504. doi: 10.1016/S2468-1253(22)00083-8.
3
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply.可切除肝细胞癌的新辅助免疫治疗——作者回复
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):505. doi: 10.1016/S2468-1253(22)00122-4.
4
Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies.肝细胞癌的免疫疗法：生物标志物研究的挑战。
J Chin Med Assoc. 2021 Feb 1;84(2):121-122. doi: 10.1097/JCMA.0000000000000458.
5
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.肝细胞癌的免疫治疗：现状与未来展望
Front Immunol. 2021 Oct 4;12:765101. doi: 10.3389/fimmu.2021.765101. eCollection 2021.
6
Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?".回复：“肝细胞癌患者接受免疫治疗的预后预测：我们做到了吗？”
J Hepatol. 2022 Apr;76(4):988-989. doi: 10.1016/j.jhep.2021.12.025. Epub 2021 Dec 31.
7
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma.COSMIC-312：肝细胞癌不断增加的免疫治疗谜团
Lancet Oncol. 2022 Oct;23(10):e441. doi: 10.1016/S1470-2045(22)00497-1.
8
Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.肝细胞癌：手术切除与手术切除联合术前及术后局部区域免疫治疗-化疗。一项前瞻性随机研究。
Anticancer Res. 1995 Mar-Apr;15(2):543-50.
9
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指标。
J Hepatol. 2022 May;76(5):1232-1233. doi: 10.1016/j.jhep.2021.12.033. Epub 2022 Jan 19.
10
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".回复：“CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指南”。
J Hepatol. 2022 May;76(5):1233-1234. doi: 10.1016/j.jhep.2022.02.002. Epub 2022 Feb 14.